80841-35-6

Basic information

• Product Name: 1H-Benzimidazole,2-chloro-1-propyl-(9CI)
• Synonyms: 1H-Benzimidazole,2-chloro-1-propyl-(9CI)
• CAS NO: 80841-35-6
• Molecular Formula: C₁₀H₁₁ClN₂
• Molecular Weight: 194.66074
• Product Categories: BENZIMIDAZOLE
• Mol File: 80841-35-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Benzimidazole,2-chloro-1-propyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole,2-chloro-1-propyl-(9CI)(80841-35-6)
• EPA Substance Registry System: 1H-Benzimidazole,2-chloro-1-propyl-(9CI)(80841-35-6)

Safety Data

• Hazardous Substances Data: 80841-35-6(Hazardous Substances Data)

Usage

Properties

Belongs to the benzimidazole class of compounds
Contains a 2-chloro-1-propyl substituent
Potential use as a pharmaceutical intermediate in the synthesis of various drugs
Potential use as a building block in organic synthesis
Studied for its potential biological activities, including antifungal and antimicrobial properties
Possible applications in the field of pest control and crop protection

Specific content

1H-Benzimidazole,2-chloro-1-propyl-(9CI) is a chemical compound.
It has several potential applications in various industries.

Upstream product

• 4857-06-1 2-chloro-1H-benzoimidazole 
• 106-94-5 propyl bromide 
• 895581-98-3 2-chloro-1-[(3-phenylselanyl)propyl]-1H-benzo[d]imidazole 

Downstream Products

• 388574-71-8 (1-propyl-1H-benzoimidazol-2-yl)-hydrazine 

Relevant articles and documents

Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903

The transient receptor potential cation channel 5 (TRPC5) has been previously shown to affect podocyte survival in the kidney. As such, inhibitors of TRPC5 are interesting candidates for the treatment of chronic kidney disease (CKD). Herein, we report the synthesis and biological characterization of a series of N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors. Work reported here evaluates the benzimidazole scaffold and substituents resulting in the discovery of AC1903, a TRPC5 inhibitor that is active in multiple animal models of CKD.

New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation

A series of 2-piperazinylbenzimidazole derivatives were prepared and evaluated as 5-HT3 receptor antagonists. Their 5-HT3 receptor affinities were evaluated by radioligand binding assays, and their abilities to inhibit the 5-HT-induced Bezold-Jarisch reflex in anesthetized rats were determined. Compound 7e (lerisetron, pK(i) = 9.2) exhibited higher affinity for the 5- HT3 receptor than did tropisetron and granisetron, while compound 7q (pK(i) = 7.5) had very low affinity for this receptor, showing that substitution on the N1 atom of the benzimidazole ring is essential for affinity and activity. The effect of substitution on the aromatic ring of benzimidazole by several substituents in different positions is also discussed. A strong correlation between the 5-HT3 antagonistic activity of the studied compounds and the position of substitution on the aromatic ring was established. Thus, while the 4-methoxy derivative 7m showed weak affinity for the 5-HT3 receptor (pK(i) = 6.7), the 7-methoxy derivative 7n exhibited the highest affinity (pK(i) = 9.4). Compounds 7e and 7n are now under further investigation as drugs for the treatment of nausea and emesis evoked by cancer chemotherapy and radiation.